Get insights into Vir Biotechnology's Q1 2025 earnings call, including ECLIPSE Phase III trial progress, oncology updates, and financial highlights.

Analysts estimate that Vir Biotechnology will report an earnings per share (EPS) of $-0.84. Vir Biotechnology bulls will hope ...

Despite a significant revenue drop, Vir Biotechnology Inc (VIR) maintains a strong cash position and progresses in key ...

Northway Biotech, a biopharmaceutical contract development and manufacturing organization (CDMO), today announced the ...

The ancestor of the virus that causes COVID-19 left its point of origin in Western China or Northern Laos just several years ...

A type of virus thought to be a 'mere curiosity' is plentiful in one common bacteria, and possibly others, a research team has found. The discovery improves understanding of how viruses work and could ...

The influenza virus manipulates the body's gene regulation system to accelerate its own spread. A new study also shows that an already approved drug could help strengthen immune defenses -- though its ...

BioPharm International® sat down with Noah Kopcho, field application scientist at Gyros Protein Technologies, to talk about ...

Provides ReciBioPharm's customers with access to NewBiologix's Xcell-Eng-HEK293 cell lines for advanced therapies <l ...

Have you ever wondered about what became of COVID vaccine companies after the pandemic settled down? Find out in this article ...

Scientists suspect a deadly virus is behind an unusually large number of fish deaths in Lake Huron this spring, where ...